Tanya B. Dorff, MD

Tanya B. Dorff, MD, is section chief of the Genitourinary Disease Program and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope in Duarte, California.

Articles

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

April 1st 2025

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

December 18th 2023

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

December 18th 2023

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression

December 15th 2023

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Evolving Paradigms in the Detection and Treatment of Prostate Cancer

December 15th 2023

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC

March 10th 2023

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.

Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC

January 12th 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC

January 10th 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Metastatic CRPC Management: Future Directions in Care

January 9th 2023

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.

Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC

January 4th 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer

January 2nd 2023

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy

January 2nd 2023

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin

December 26th 2022

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.

Interpreting Data From the CARD Trial in Metastatic CRPC

December 19th 2022

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC

December 19th 2022

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC

December 12th 2022

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

Overview on Metastatic CRPC and Available Treatment Options

December 12th 2022

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

Practical Considerations in Selecting Therapy for Metastatic CRPC

August 23rd 2022

Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.

What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?

August 23rd 2022

Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.